This experimental pill helped people lose about 16% of their body weight after about a year of treatment ...
(Competitive Insight/Unsplash) While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, ...
Officials wrote that Novo Nordisk had failed to failed to report ‘serious and unexpected’ adverse drug experiences ...
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...
The Danish drugmaker said it plans to offer the medicines for $675 per month starting in January 2027, representing a 50% ...
A new battle between these longtime rival companies will likely go the same way as their previous battles.
By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster ...
TheHealthSite on MSN
Ozempic, Wegovy and Mounjaro: Here’s what happens when you stop taking GLP-1 drugs
Scientists raise a very significant message that despite halting the use of GLP-1 drugs, reduced fat does not inevitably have to be regained over time.
A new study reports that GLP-1 semaglutide medications may help reverse the effects of osteoarthritis in the joints by ...
A few months into GLP-1 treatment, many patients encounter an unexpected and distressing side effect: significant hair loss.
The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results